At what estimated glomerular filtration rate (eGFR) threshold are statins no longer indicated?

Statins Remain Indicated at All eGFR Levels in CKD (No Lower Threshold for Discontinuation)

There is no eGFR threshold at which statins should be discontinued in patients with chronic kidney disease—statins remain indicated even in advanced CKD stages 4-5 (eGFR 15-29 mL/min/1.73 m²) until dialysis initiation. 1

Key Guideline Recommendations

The KDIGO guideline explicitly recommends statin therapy for adults ≥50 years with eGFR <60 mL/min/1.73 m² without an upper or lower eGFR limit for treatment 1. The evidence base extends down to very low kidney function:

• SHARP trial enrolled patients with mean eGFR of 27 ± 13 mL/min/1.73 m² and demonstrated cardiovascular benefit 1
• Patients with serum creatinine ≥1.7 mg/dL (men) or ≥1.3 mg/dL (women) showed clear benefit from statin therapy 1
• Recent real-world data confirms that 65.7% of ASCVD patients with eGFR <30 mL/min/1.73 m² appropriately receive high-intensity statins 2

Mortality Benefit Across CKD Stages

Statins reduce all-cause mortality even in advanced CKD. A 2026 Swedish cohort study of 7,177 adults ≥50 years with eGFR <60 mL/min/1.73 m² showed:

• 38% reduction in 3-year mortality risk (HR 0.82,95% CI: 0.72-0.92) 3
• Mortality rates: 42 vs 57 deaths per 1,000 person-years with vs without statins 3
• Benefit persisted after adjusting for CKD stage, age, and comorbidities 3

Dose Adjustments (Not Discontinuation)

The only modification needed is dose intensity, not whether to prescribe:

• KDIGO recommends avoiding high-intensity statins when eGFR <60 mL/min/1.73 m² due to polypharmacy concerns and trial dosing patterns 1
• However, this conflicts with FDA labeling: atorvastatin requires no dose adjustment for kidney disease, and rosuvastatin only requires adjustment when creatinine clearance <30 mL/min/1.73 m² 1
• In practice, 67.6% of patients with eGFR <30 receive rosuvastatin doses exceeding FDA recommendations, suggesting clinicians prioritize cardiovascular benefit 2

Additional Renal Benefits

Beyond cardiovascular protection, statins slow eGFR decline in moderate-severe CKD:

• Meta-analysis of 14,393 patients with stage 3-4 CKD showed statins reduced eGFR decline by 0.26 mL/min/1.73 m²/year (P=0.0017) 4
• Baseline mean eGFR was 49-53 mL/min/1.73 m² with benefits in both primary and secondary prevention 4

Clinical Algorithm

1. eGFR ≥60: Use standard intensity statins per cardiovascular risk
2. eGFR 30-59: Continue statins; consider moderate-intensity per KDIGO (though FDA labeling permits higher doses for most statins)
3. eGFR 15-29: Continue statins; use moderate-intensity; rosuvastatin may require dose reduction per FDA label
4. Dialysis initiation: This is when statin benefit becomes uncertain—do NOT initiate statins in dialysis patients, but continuation in those already on therapy is reasonable

Common Pitfalls

• Do not discontinue statins based on declining eGFR alone—the mortality benefit persists even in advanced CKD 3
• The SHARP trial evidence specifically supports treatment in patients with severely reduced kidney function (mean eGFR 27) 1
• Only 38% of eligible CKD patients receive statins, representing significant undertreatment 3